Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

Joseph J. Eron, Jr., MD
Program Director
Daniel R. Kuritzkes, MD
Program Director
Paul E. Sax, MD
Released: June 11, 2020
Back Next


There are currently more than 30 individual ARV agents approved by the FDA for the treatment of HIV and more than 10 coformulated combination products. Among the numerous options available today, how can clinicians select the optimal treatment for an individual patient? This module will cover the basic principles behind regimen selection; it will then explore some commonly encountered patient scenarios that make particular regimens favored in certain settings.

The goals of initial therapy, as defined by the DHHS guidelines, include maximal and durable suppression of plasma HIV-1 RNA, restoration and preservation of immune function, reduction of HIV-associated morbidity, prolongation of the duration and quality of survival, and reduction of HIV transmission.[1] This last goal is achieved when HIV-1 RNA is suppressed to below the lower limits of detection of currently available assays; today, those limits are HIV-1 RNA < 20-50 copies/mL. The established efficacy of HIV treatment-as-prevention is generally referred to as U = U, or undetectable = untransmittable.

Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings